Gracell biotechnologies inc.

Major-Pharmaceuticals

GRCL


Executive/
Director

Price

  • Last Close
  • $ 10.25
    $ +0.01 0.05 %
    Feb 21, 2024
  • 52-Week High/Low
  • $10.35 - $2.43
  • YTD
  • 2.1%

  • Trading Volume
  • 6,417,173
  • Market Cap Full
  • $ 3.5B
  • Shares Outstanding
  • 338.5M
    Dec 31, 2022
2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Q1 - - - - - - - -61.3% -19.1% 2.1%
Q2 - - - - - - -15.6% 135% 104.8% -
Q3 - - - - - - 6.7% -41.5% -24.4% -
Q4 - - - - - - -56.5% -28.6% 287.6% -
J F M A M J J A S O N D
2024 1.8% 0.3% - - - - - - - - - -
2023 -6.5% -6.5% -7.5% -6.5% 57.5% 39.1% -1.1% -13% -12.2% 16.7% 44.9% 106.2%
    2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
    0%0%0%0%0%0%0%0%-62%337%2%

Earnings

2020 2021 2022 2023
Q1 - -0.25 -0.35 -0.35
Q2 - -0.22 -0.3 -0.30
Q3 - -0.3 -0.35 -0.10
Q4 - -0.33 -0.30 -
A -0.4 -0.2 -0.3 -0.75

Annual Returns

52 Week
High/Low

Annual
Earnings

Chart

Trading Volume

2020 2021 2022
Mar - - -
Jun - - -
Sep - - -
Dec 272.8 346.3 338.5

Financial Ratios

20222021202020192018
Asset Management
Inventory / Stock Turnover - - - - -
Fixed Asset Turnover - - - - -
Total Asset Turnover - - - - -
Leverage
Debt Ratio - - 0.1 - -
Debt – Equity Ratio - - -0.1 - -
Interest Coverage 30.3 36.5 33 11 -
Equity multiplier 0.1 0.1 -0.3 -0.2 -